CN110678180A - 治疗癌症的液体剂型 - Google Patents

治疗癌症的液体剂型 Download PDF

Info

Publication number
CN110678180A
CN110678180A CN201880035207.9A CN201880035207A CN110678180A CN 110678180 A CN110678180 A CN 110678180A CN 201880035207 A CN201880035207 A CN 201880035207A CN 110678180 A CN110678180 A CN 110678180A
Authority
CN
China
Prior art keywords
compound
malate
pharmaceutically acceptable
less
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880035207.9A
Other languages
English (en)
Chinese (zh)
Inventor
K·沙
G·施瓦布
S·莱西
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exerie Exis Co
Original Assignee
Exerie Exis Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exerie Exis Co filed Critical Exerie Exis Co
Publication of CN110678180A publication Critical patent/CN110678180A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880035207.9A 2017-06-09 2018-06-08 治疗癌症的液体剂型 Pending CN110678180A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762517736P 2017-06-09 2017-06-09
US62/517,736 2017-06-09
US201762520768P 2017-06-16 2017-06-16
US62/520,768 2017-06-16
PCT/US2018/036703 WO2018227119A1 (en) 2017-06-09 2018-06-08 Liquid dosage forms to treat cancer

Publications (1)

Publication Number Publication Date
CN110678180A true CN110678180A (zh) 2020-01-10

Family

ID=62779087

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880035207.9A Pending CN110678180A (zh) 2017-06-09 2018-06-08 治疗癌症的液体剂型

Country Status (10)

Country Link
US (3) US11504362B2 (enExample)
EP (1) EP3634413A1 (enExample)
JP (1) JP7249962B2 (enExample)
KR (1) KR102647794B1 (enExample)
CN (1) CN110678180A (enExample)
AU (1) AU2018279834B2 (enExample)
CA (1) CA3065560A1 (enExample)
MX (1) MX2019014298A (enExample)
UA (1) UA126402C2 (enExample)
WO (1) WO2018227119A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033513B1 (ru) * 2011-02-10 2019-10-31 Exelixis Inc Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения
CN110678180A (zh) 2017-06-09 2020-01-10 埃克塞里艾克西斯公司 治疗癌症的液体剂型
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
CN106715397A (zh) * 2014-07-31 2017-05-24 埃克塞里艾克西斯公司 制备氟‑18标记的卡博替尼及其类似物的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
DK2387563T4 (da) * 2009-01-16 2022-07-18 Exelixis Inc Malatsalt af n-(4-{ [ 6, 7-bis(methyloxy)quinolin-4-yl]oxy}phenyl-n'-(4-fluorphenyl)cyclopropan-1,1-dicarboxamid, og krystallinske former deraf til behandling af cancer
EP2632430B1 (en) 2010-10-29 2018-06-06 Troikaa Pharmaceuticals Ltd Nasal compositions of vitamin b12
BR212013028314U2 (pt) 2011-05-02 2015-11-03 Exelixis Inc método para tratar câncer e dor de câncer de osso
EP2758057B1 (en) * 2011-09-22 2017-05-31 Exelixis, Inc. Method for treating osteoporosis
ITRM20120331A1 (it) 2012-07-12 2014-01-13 Guidotti & C Spa Labor Composizioni pediatriche orali liquide contenenti nepadutant.
BR112015001838B1 (pt) 2012-07-27 2022-10-25 Izumi Technology, Llc Composição de inibidor de efluxo
MX384828B (es) 2014-02-14 2025-03-14 Exelixis Inc Formas solidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboracion y metodos de uso.
US20170042880A1 (en) 2014-04-25 2017-02-16 Exelixis, Inc. Method of Treating Lung Adenocarcinoma
CN110678180A (zh) 2017-06-09 2020-01-10 埃克塞里艾克西斯公司 治疗癌症的液体剂型

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120070368A1 (en) * 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
CN106715397A (zh) * 2014-07-31 2017-05-24 埃克塞里艾克西斯公司 制备氟‑18标记的卡博替尼及其类似物的方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
F. MICHAEL YAKES等: "Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis,and Tumor Growth", 《MOL CANCER THER》 *
FRAUKE BENTZIEN等: "In Vitro and in vivo Activity of Cabozantinib (XL184),an inhibitor of RET,MET,and VEGFR2,in a Model of Medullary Thyroid Cancer", 《THYROID.》 *
QIUHONG YANG等: "Cabozantinib Loaded DSPE-PEG2000 Micelles as Delivery System: Formulation, Characterization and Cytotoxicity Evaluation", 《BAOJ PHARM SCI.》 *
R. KURZROCK等: "Activity of XL184(Cabozantinib), an oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer", 《JOURNAL OF CLINICAL ONCOLOGY》 *
STEVEN LACY等: "Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites", 《DRUG METABOLISM AND DISPOSITION》 *
方亮: "《药用高分子材料学》", 31 August 2015, 中国医药科技出版社 *

Also Published As

Publication number Publication date
WO2018227119A1 (en) 2018-12-13
UA126402C2 (uk) 2022-09-28
EP3634413A1 (en) 2020-04-15
US20240307367A1 (en) 2024-09-19
US20200268737A1 (en) 2020-08-27
AU2018279834A1 (en) 2020-01-16
BR112019025110A2 (pt) 2020-09-01
JP2020523317A (ja) 2020-08-06
US20230301978A1 (en) 2023-09-28
CA3065560A1 (en) 2018-12-13
US11504362B2 (en) 2022-11-22
KR20200014903A (ko) 2020-02-11
KR102647794B1 (ko) 2024-03-15
JP7249962B2 (ja) 2023-03-31
MX2019014298A (es) 2020-02-03
US12016854B2 (en) 2024-06-25
AU2018279834B2 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
US12016854B2 (en) Liquid dosage forms to treat cancer
US12036224B2 (en) Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredient
CN108472242A (zh) 治疗癌症的药物组合
JP2012520261A (ja) オキシコドンおよびナロキソンを含む即時放出医薬組成物
US20100099723A1 (en) Bioavailable compositions of metaxalone and processes for producing the same
JP2023540223A (ja) Ｃｒｆ受容体アンタゴニストおよび使用方法
JP6263271B2 (ja) 心血管疾患の治療または予防に用いるためのコレステリルエステル転送タンパク質（ｃｅｔｐ）阻害剤および当該阻害剤を含む医薬組成物
JP2020530026A (ja) 線維性疾患の治療における使用のための化合物及びその医薬組成物
JP2022518788A (ja) オピオイド鎮痛耐性を治療するためのｍＧｌｕＲ５アンタゴニストの使用
WO2019004465A1 (ja) ペマフィブラートを含有する医薬
BR112019025110B1 (pt) Composição farmacêutica líquida e seus usos
WO2022106621A1 (en) Selexipag for use via intracolonic administration
US20210137903A1 (en) Anti-androgens for the treatment of prostrate cancer
EA043824B1 (ru) Жидкие лекарственные формы для лечения рака
JP2022534886A (ja) エストロゲン受容体アルファ阻害剤の経口剤形を用いて癌を治療する方法
US20070027121A1 (en) Method of treatment of diarrhea-predominant IBS in a female subject receiving contraceptive therapy
Souza et al. Evaluation of the relative bioavailability between two formulations of olmesartan medoxomil 40mg, in orodispersible tablet form and coated tablet form, in healthy participants of both sexes
JP2005518432A (ja) 経口トリメトベンズアミド製剤および方法
JP2025519466A (ja) フロログルシノール製剤および使用方法
CN119868295A (zh) 一种cdk抑制剂固体药物组合物及其制备方法
WO2020144646A1 (en) Apalutamide dispersed in applesauce for treating prostate cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200110

WD01 Invention patent application deemed withdrawn after publication